Inventor · disambiguated record
Stacie M. Goldberg
Also filed as: GOLDBERG STACIE M
15 granted patents·4 pending applications·632 citations·filing 2013–2024
96Inventor score
Files withBRISTOL MYERS SQUIBB CO19
Top patents by PatentIndex Score
19 records- 0198US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 0298US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 0398US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 0498US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 0598US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 0698US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 0798US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0898US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0998US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 1098US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 1198US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 1297US10584170B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 10, 2020·23 cites·27 claims
- 1397US10577423B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 3, 2020·23 cites·27 claims
- 1497US10316090B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·29 cites·27 claims
- 1597US9212224B2Antibodies that bind PD-L1 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 15, 2015·135 cites·2 claims
- 1692US2024417471A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1786US2024002512A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1886US2024034793A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1975US2020308282A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stacie M. Goldberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →